AstraZeneca vs NVIDIA: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and NVIDIA side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

3. 1993NVIDIA

   Founding in Santa Clara

   Jensen Huang, Chris Malachowsky, and Curtis Priem founded NVIDIA on April 5, 1993, with a focus on 3D graphics for gaming and multimedia. The founding set the company on a parallel-processing path long before AI infrastructure became the main market.

4. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

5. 1999NVIDIA

   GPU Category Defined

   NVIDIA introduced the graphics processing unit concept in 1999. The milestone mattered because it framed graphics hardware as a specialized processor, a technical idea that later carried into accelerated computing and AI workloads.

6. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

7. 2006AstraZeneca

   Acquisition of Cambridge Antibody Technology

   AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

8. 2006NVIDIA

   CUDA Opens GPUs to General Computing

   CUDA opened GPU parallel processing to scientists, researchers, and developers outside graphics. It became the software foundation that made NVIDIA hardware useful for machine learning, simulation, and other compute-heavy workloads.

9. 2007AstraZeneca

   Acquisition of MedImmune for $15.6 Billion

   AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

10. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

11. 2012NVIDIA

    AlexNet Shows GPU Value for Deep Learning

    The AlexNet breakthrough used NVIDIA GPUs to win the ImageNet competition. The event helped convince researchers and engineers that GPUs could accelerate neural-network training at a scale CPUs could not match.

12. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

13. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

14. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

15. 2016NVIDIA

    DGX-1 AI Supercomputer

    Nvidia introduced the DGX-1 deep-learning supercomputer in 2016, its first system built specifically for artificial intelligence.

16. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

17. 2018NVIDIA

    RTX Brings Real-Time Ray Tracing to Graphics

    NVIDIA RTX brought real-time ray tracing into the company's graphics roadmap. The product line kept gaming and professional visualization tied to AI-enhanced rendering while Data Center was becoming more important.

18. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

19. 2020NVIDIA

    Mellanox Acquisition Adds Networking

    NVIDIA completed the Mellanox acquisition for about $7 billion. The deal mattered because large AI and high-performance-computing clusters depend on fast networking between accelerators, not only on individual GPU speed.

20. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

21. 2022NVIDIA

    Arm Acquisition Terminated

    NVIDIA and SoftBank terminated the proposed Arm acquisition because of significant regulatory challenges. The failed deal showed how closely governments watch control points in semiconductor architecture.

22. 2022NVIDIA

    Hopper H100 Announced

    Nvidia announced the Hopper-architecture H100 data-center GPU in March 2022.

23. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

24. 2023NVIDIA

    Grace CPU Enters Data Center Roadmap

    NVIDIA introduced its first data-center CPU, Grace, for large-scale AI and high-performance computing. The milestone expanded the platform from GPUs and networking into CPU-GPU system design.

25. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

26. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

27. 2024NVIDIA

    Blackwell Architecture Launched

    NVIDIA launched Blackwell as a data-center-scale architecture combining GPUs, CPUs, DPUs, interconnects, switch chips, systems, and networking adapters. The architecture became central to FY2026 Data Center demand.

28. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

29. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

30. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

31. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

32. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

33. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

34. 2026NVIDIA

    $215.9B FY2026 Revenue

    NVIDIA reported $215.9 billion of FY2026 revenue, $193.7 billion of Data Center revenue, and $120.1 billion of net income. The result showed how far AI infrastructure had moved the company beyond its original PC graphics market.

Acquisitions

Questions about AstraZeneca vs NVIDIA